Leukemia Research
Volume 33, Issue 2 , Pages 232-236 , February 2009

Levels of beta 2 microglobulin have a prognostic relevance for patients with myelodysplastic syndrome with regard to survival and the risk of transformation into acute myelogenous leukemia

  • Frank Neumann

      Affiliations

    • Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University Duesseldorf, Moorenstr. 5, 40225 Duesseldorf, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49 211 8117720; fax: +49 211 8118853.
    • ,
  • Norbert Gattermann

      Affiliations

    • Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University Duesseldorf, Moorenstr. 5, 40225 Duesseldorf, Germany
    • ,
  • Hans-Ulrich Barthelmes

      Affiliations

    • Institute of Clinical Chemistry and Laboratory Diagnostics, Heinrich-Heine-University Duesseldorf, Moorenstr. 5, 40225 Duesseldorf, Germany
    • ,
  • Rainer Haas

      Affiliations

    • Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University Duesseldorf, Moorenstr. 5, 40225 Duesseldorf, Germany
    • ,
  • Ulrich Germing

      Affiliations

    • Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University Duesseldorf, Moorenstr. 5, 40225 Duesseldorf, Germany

Received 11 April 2008 ,Revised 2 June 2008 ,Accepted 3 June 2008.

References 

  1. Bennett JM. A comparative review of classification systems in myelodysplastic syndromes (MDS). Semin Oncol. 2005;32:3–10
  2. Germing U, Hildebrandt B, Pfeilstocker M, Nosslinger T, Valent P, Fonatsch C, et al. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia. 2005;19:2223–2231
  3. Gatto S, Ball G, Onida F, Kantarjian HM, Estey EH, Beran M. Contribution of β-2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndrome (MDS). Blood. 2003;102:1622–1625
  4. Avilés A, Zepeda G, Díaz-Maqueo JC, Rodriguez L, Guzmán R, García EL, et al. Beta 2 microglobulin levels as an indicator of prognosis in diffuse large cell lymphoma. Leuk Lymphoma. 1992;7:135–138
  5. Litam P, Swan F, Cabanillas F, Tucker SL, McLaughlin P, Hagemeister FB, et al. Prognostic value of serum beta-2 microglobulin in low-grade lymphoma. Ann Intern Med. 1991;114:855–860
  6. Kyle RA. Prognostic factors in multiple myeloma. Stem Cells. 1995;13:56–63
  7. Keating MJ, O’Brien S, Robertson L, Huh Y, Kantarjian H, Plunkett W. Chronic lymphocytic leukemia: correlation of response and survival. Leuk Lymphoma. 1993;11:167–175
  8. Kantarjian HM, Smith T, Estey E, Polyzos A, O’Brien S, Pierce S, et al. Prognostic significance of elevated serum beta 2-microglobulin levels in adult acute lymphocytic leukemia. Am J Med. 1992;93:599–604
  9. Rodriguez J, Cortes J, Talpaz M, O’Brien S, Smith TL, Rios MB, et al. Serum beta-2 microglobulin levels are a significant prognostic factor in Philadelphia chromosome-positive chronic myelogenous leukemia. Clin Cancer Res. 2000;6:147–152
  10. Onida F, Kantarjian HM, Smith TL, Ball G, Keating MJ, Estey EH, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood. 2002;99:840–849
  11. Albitar M, Johnson M, Do KA, Day A, Jilani I, Pierce S, et al. Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy. Leukemia. 2007;21:480–488
  12. Tsimberidou AM, Kantarjian HM, Wen S, O’Brien S, Cortes J, Wierda WG, et al. The Prognostic significance of serum {beta}2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1180 patients. Clin Cancer Res. 2008;14:721–730
  13. Schardijn GH, Statius van Eps LW. Beta 2-microglobulin: its significance in the evaluation of renal function. Kidney Int. 1987;32:635–641
  14. Haase D, Germing U, Schanz J, Pfeilstöcker M, Nösslinger T, Hildebrandt B, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007;110:4385–4395
  15. Csiba A, Whitwell HL, Moore M. Distribution of histocompatibility and leucocyte differentiation antigens in normal human colon and in benign and malignant colonic neoplasms. Br J Cancer. 1984;50:699–709
  16. Walton GR, McCue PA, Graham SD. B-2-microglobulins as a differentiation marker in bladder cancer. J Urol. 1986;136:1197–1200
  17. Swan F, Velasquez WS, Tucker S, Redman JR, Rodriguez MA, McLaughlin P, et al. A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels. J Clin Oncol. 1989;7:1518–1527

PII: S0145-2126(08)00279-8

doi: 10.1016/j.leukres.2008.06.003

Leukemia Research
Volume 33, Issue 2 , Pages 232-236 , February 2009

Article Tools

* Image Usage & Resolution